The FDA approval of Selarsdi 130 mg/26 ml in a single-dose vial for intravenous infusion expands the label to include ...

The US Food and Drug Administration (FDA) has approved a new presentation of Alvotech and Teva Pharmaceuticals’ SELARSDI ...

Selarsdi (ustekinumab-aekn), a biosimilar to Stelara (ustekinumab), is expanded to the indications to include treatment of Crohn disease ...

Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the FDA has ...

Alvotech (ALVO) has released an update. Alvotech and Teva Pharmaceuticals have received U.S. FDA approval for a new intravenous presentation of ...

Teva Pharmaceutical Industries (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) said the FDA has expanded labeling for its biosimilar ...

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to ...

The US Food and Drug Administration (FDA) has approved a new presentation of Alvotech and Teva Pharmaceuticals’ SELARSDI (ustekinumab-aekn), expanding its label to include the treatment of ...

Alvotech (ALVO) has released an update. Alvotech and Teva Pharmaceuticals have received U.S. FDA approval for a new intravenous presentation of SELARSDI, enhancing its use for Crohn’s disease ...